万泰生物
(603392)
| 流通市值：480.09亿 | | | 总市值：480.09亿 |
| 流通股本：12.64亿 | | | 总股本：12.64亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 523,344,880.88 | 1,818,967,457.87 | 1,498,369,947.13 | 843,561,860.09 |
| 营业收入 | 523,344,880.88 | 1,818,967,457.87 | 1,498,369,947.13 | 843,561,860.09 |
| 二、营业总成本 | 518,061,923.75 | 2,322,416,853.65 | 1,780,002,318.88 | 1,020,748,464.07 |
| 营业成本 | 157,747,644.58 | 921,826,885.82 | 695,514,313.91 | 334,452,600.67 |
| 税金及附加 | 5,218,761.55 | 21,478,347.15 | 13,204,225.16 | 11,084,588.3 |
| 销售费用 | 144,738,840.12 | 445,674,238.13 | 347,802,633.94 | 217,080,093.66 |
| 管理费用 | 95,242,406.83 | 384,010,208.9 | 289,303,494.75 | 192,690,508.21 |
| 研发费用 | 109,793,036.51 | 560,796,914.39 | 445,519,959.69 | 276,466,361.42 |
| 财务费用 | 5,321,234.16 | -11,369,740.74 | -11,342,308.57 | -11,025,688.19 |
| 其中:利息费用 | 1,577,407.31 | 6,457,746.22 | 5,149,053.08 | 13,605,360.7 |
| 其中:利息收入 | 8,151,517.09 | 32,898,979.54 | 17,628,843.51 | 25,462,600.15 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 5,629,422.24 | 48,297,071.98 | 23,076,254.44 | 17,591,273.78 |
| 加:投资收益 | 14,724,694.43 | 66,215,195.97 | 66,510,992.9 | 44,357,628.65 |
| 资产处置收益 | 26,672.57 | 60,231,327.31 | -51,055.19 | -146,644.6 |
| 资产减值损失(新) | -16,753,134.21 | -207,361,022.12 | -16,894,151.74 | -23,426,159.84 |
| 信用减值损失(新) | -75,460,630.32 | -21,570,698.36 | -49,990,223.77 | -57,429,999.74 |
| 其他收益 | 7,868,265.59 | 88,413,738.63 | 74,538,821.37 | 56,896,996.43 |
| 四、营业利润 | -58,681,752.57 | -469,223,782.37 | -184,441,733.74 | -139,343,509.3 |
| 加:营业外收入 | 218,074.47 | 797,030.08 | 678,368.2 | 588,873.86 |
| 减:营业外支出 | 1,406,012.37 | 12,459,004.12 | 8,093,057.21 | 6,928,222.47 |
| 五、利润总额 | -59,869,690.47 | -480,885,756.41 | -191,856,422.75 | -145,682,857.91 |
| 减:所得税费用 | -14,982,426.78 | -66,922,226.97 | -17,965,068.19 | -190,628.13 |
| 六、净利润 | -44,887,263.69 | -413,963,529.44 | -173,891,354.56 | -145,492,229.78 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -44,887,263.69 | -413,963,529.44 | -173,891,354.56 | -145,492,229.78 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -42,983,830.73 | -398,267,667.27 | -173,421,950.63 | -144,038,127.02 |
| 少数股东损益 | -1,903,432.96 | -15,695,862.17 | -469,403.93 | -1,454,102.76 |
| 扣除非经常损益后的净利润 | -64,602,901.66 | -622,669,164.2 | -307,618,892.32 | -242,605,985.91 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.03 | -0.31 | -0.14 | -0.11 |
| (二)稀释每股收益 | -0.03 | -0.31 | -0.14 | -0.11 |
| 九、综合收益总额 | -44,887,263.69 | -413,963,529.44 | -173,891,354.56 | -145,492,229.78 |
| 归属于母公司股东的综合收益总额 | -42,983,830.73 | -398,267,667.27 | -173,421,950.63 | -144,038,127.02 |
| 归属于少数股东的综合收益总额 | -1,903,432.96 | -15,695,862.17 | -469,403.93 | -1,454,102.76 |
| 公告日期 | 2026-04-28 | 2026-04-21 | 2025-10-30 | 2025-08-21 |
| 审计意见(境内) | | 标准无保留意见 | | |